Progress in genetic engineering led to the emergence of some viruses as potent anticancer
therapeutics. These oncolytic viruses combine self-amplification with dual antitumor action …

Viruses and tumors are two pathologies that negatively impact human health, but what
occurs when a virus encounters a tumor? A global consensus among cancer patients …

We present here the results of a first-in-human, first-in-child trial for patients with
relapsed/refractory solid tumors using Celyvir, an advanced therapy medicine that combines …

Background Osteosarcoma is the most common malignant solid tumor that affects bones,
however, survival rates of patients with relapsed osteosarcoma have not improved in the last …

Oncolytic viruses (OVs) have emerged as a very promising anti-cancer therapeutic strategy
in the past decades. However, despite their pre-clinical promise, many OV clinical …

Oncolytic viruses can target neoplasms, triggering oncolytic and immune effects. Their
delivery to melanoma lesions remains challenging. Bone-marrow-derived mesenchymal …

Mesenchymal stem cells (MSCs) have the ability to migrate into tumor sites and release
growth factors to modulate the tumor microenvironment. MSC therapy have shown a dual …

Introduction Many pediatric patients with malignant tumors continue to suffer poor outcomes.
The current standard of care includes maximum safe surgical resection followed by …

Human multipotent mesenchymal stromal cells (hMSCs) are of significant therapeutic
interest due to their ability to deliver oncolytic adenoviruses to tumors. This approach is also …

Neuroblastoma (NB) is a common and deadly malignancy mostly observed in children.
Evolution of therapeutic options for NB led to the addition of immunotherapeutic modalities …